


**Product Name** : LY3023414  
**Cat. No.** : PC-43082  
**CAS No.** : 1386874-06-1  
**Molecular Formula** : C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub>  
**Molecular Weight** : 406.4775  
**Target** : PI3K  
**Solubility** : 10 mM in DMSO



## Biological Activity

LY3023414 is a potent, dual **PI3K/mTOR** inhibitor with IC<sub>50</sub> of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 165 nM and 4.24 nM for PI3K $\alpha$ , PI3K $\beta$ , PI3K $\delta$ , PI3K $\gamma$ , mTOR and DNA-PK, respectively.

LY3023414 inhibits the phosphorylation of AKT at position T308 with IC<sub>50</sub> of 106 nM in the PTEN-deficient U87 MG glioblastoma cell line, inhibits phosphorylation of AKT at position S473 (IC<sub>50</sub>=94.2 nM) by mTORC2 as well as phosphorylation of mTORC1 kinase targets p70S6K (position T389; IC<sub>50</sub>=10.6 nM).

LY3023414 causes G1 cell-cycle arrest and shows broad antiproliferative activity in cancer cell panel screens.

LY3023414 exhibits antitumor activity in multiple xenograft models.

## References

Smith MC, et al. *Mol Cancer Ther.* 2016 Oct;15(10):2344-2356.

Zaidi AH, et al. *Ann Surg.* 2017 Jul;266(1):91-98.

Wei L, et al. *Oncotarget.* 2016 Nov 22;7(47):76374-76389.

Zheng L, et al. *Oncotarget.* 2017 Oct 27;8(58):98964-98973.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com